US intelligence officials say Chinese pharma companies are risking national security at a time when Washington is considering multiple bills targeting those firms access to funds

The state-owned enterprise has noticed sharp growth for its medical aesthetics business after the company became the exclusive distributor in China for Letybo, a botox product

Data compiled by Enterprise Singapore showed amount raised rose more than five times from the $86 million in 2016 to $464 million last year